Chronic Rhinosinusitis with Nasal Polyps
Conditions
Interventions
Intervention Group:Postoperative treatment with an anti-IL-5 biologic agent, administered subcutaneously in the abdomen at a dose of 100 mg every 4 weeks.
Control group:Conventional treatment
Sponsors
Chengdu Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Clinically diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP). 2.Aged 18-75 years. 3.Having undergone endoscopic sinus surgery, with all procedures performed by the same surgical team. 4.Voluntarily agrees to participate in the study and provides signed informed consent postoperatively. 5.Able to comply with scheduled follow-up visits.
Exclusion criteria
Exclusion criteria: 1.Concurrent other nasal diseases. 2.History of allergy to anti-IL-5 biologics or any of their components. 3.Comorbid severe hepatic or renal insufficiency, hematological disorders, or other serious underlying medical conditions. 4.Currently pregnant or breastfeeding. 5.Use of other biologics or immunosuppressants within the past 3 months. 6.Contraindications to the surgical procedure or poor compliance with follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NPS;VAS; | — |
Secondary
| Measure | Time frame |
|---|---|
| SNOT-22;Lund-mackay CT ;Lund-Kennedy ;Eosinophil Count; | — |
Countries
China
Contacts
Public ContactXuelian Yi
Chengdu Second People's Hospital
Outcome results
None listed